Title:
ANTI-CD37 ANTIBODY-DRUG CONJUGATE
Document Type and Number:
WIPO Patent Application WO/2023/068226
Kind Code:
A1
Abstract:
The present invention provides: an antibody that specifically binds to CD37-positive tumor cells such as B-cell malignant lymphoma; an antibody-drug conjugate that contains said antibody; a pharmaceutical composition that employs said antibody and that exhibits a therapeutic effect on a tumor; a tumor treatment method employing said pharmaceutical composition; a method for producing said antibody; a method for producing said antibody-drug conjugate; and so forth. Provided is an anti-CD37 antibody-drug conjugate in which a drug linker, which is represented by the formula below, and an antibody are bonded by means of a thioether bond (in the formula, A indicates the position at which the linker is bonded with the antibody). Specifically, provided are: a humanized anti-CD37 antibody that exhibits an internalization activity; and an antibody-drug conjugate that contains said antibody.
Inventors:
TERAUCHI TOMOKO (JP)
SHINJO YUJI (JP)
SUGAWARA HAJIME (JP)
SHUCHI YUSUKE (JP)
GOTO RIKI (JP)
SHINJO YUJI (JP)
SUGAWARA HAJIME (JP)
SHUCHI YUSUKE (JP)
GOTO RIKI (JP)
Application Number:
PCT/JP2022/038604
Publication Date:
April 27, 2023
Filing Date:
October 17, 2022
Export Citation:
Assignee:
DAIICHI SANKYO CO LTD (JP)
International Classes:
A61K47/68; A61K31/4745; A61K39/395; A61K45/00; A61P35/00; A61P35/02; C07K16/28; C07K16/46; C07K19/00; C12N15/13; C12N15/62; C12P21/08
Domestic Patent References:
| WO2017002776A1 | 2017-01-05 | |||
| WO2020022363A1 | 2020-01-30 |
Foreign References:
| JP2016532688A | 2016-10-20 | |||
| JP2014515742A | 2014-07-03 | |||
| JP2015501654A | 2015-01-19 | |||
| JP2010535483A | 2010-11-25 | |||
| JP2009502171A | 2009-01-29 |
Other References:
ARROYO-OLARTE RUBEN D., BRAVO RODRÍGUEZ RICARDO, MORALES-RÍOS EDGAR: "Genome Editing in Bacteria: CRISPR-Cas and Beyond", MICROORGANISMS, vol. 9, no. 4, pages 844, XP093058119, DOI: 10.3390/microorganisms9040844
TOSHINORI AGATSUMA: "Development of New ADC Technology with Topoisomerase I Inhibitor", THE PHARMACEUTICAL SOCIETY OF JAPAN, vol. 137, no. 5, 1 January 2017 (2017-01-01), pages 545 - 550, XP055698408, DOI: 10.1248/yakushi.16-00255-4
TOSHINORI AGATSUMA: "Development of New ADC Technology with Topoisomerase I Inhibitor", THE PHARMACEUTICAL SOCIETY OF JAPAN, vol. 137, no. 5, 1 January 2017 (2017-01-01), pages 545 - 550, XP055698408, DOI: 10.1248/yakushi.16-00255-4
Attorney, Agent or Firm:
ISHIBASHI Koki et al. (JP)
Download PDF: